TY  - JOUR
T1  - CHoosing diabetes drugs
AU  - Friedrich MJ
Y1  - 2011/05/18
N1  - 10.1001/jama.2011.636
JO  - JAMA
SP  - 1953
EP  - 1953
VL  - 305
IS  - 19
N2  - 
The study included all Danish residents older than 20 years who had begun taking either single-agent insulin secretagogues (ISs) or metformin between 1997 and 2006—a total of 107 806 people—who were observed for up to 9 years. Compared with metformin treatment, monotherapy with most ISs was associated with a greater risk of death from any cause as well as a greater risk of myocardial infarction, stroke, or death from cardiovascular disease. The ISs gliclazide and repaglinide seem to be associated with a lower risk than the other ISs.

SN  - 0098-7484
M3  - doi: 10.1001/jama.2011.636
UR  - http://dx.doi.org/10.1001/jama.2011.636
ER  -